Advances in Patient-Specific Induced Pluripotent Stem Cells Shed Light on Drug Discovery for Amyotrophic Lateral Sclerosis

Abstract

Induced pluripotent stem cells (iPSCs), which are generated through reprogramming adult somatic cells by expressing specific transcription factors, can differentiate into derivatives of the three embryonic germ layers and accelerate rapid advances in stem cell research. Neurological diseases such as amyotrophic lateral sclerosis (ALS) have benefited enormously from iPSC technology. This approach can be particularly important for creating iPSCs from patients with familial or sporadic forms of ALS. Motor neurons differentiated from the ALS-patient-derived iPSC can help to determine the relationship between cellular phenotype and genotype. Patient-derived iPSCs facilitate the development of new drugs and/or drug screening for ALS treatment and allow the exploration of the possible mechanism of ALS disease. In this article, we reviewed ALS-patient-specific iPSCs with various genetic mutations, progress in drug development for ALS disease, functional assays showing the differentiation of iPSCs into mature motor neurons, and promising biomarkers in ALS patients for the evaluation of drug candidates.

Keywords

ALS biomarker drug screening iPSC motor neuron neurodegenerative disease

Introduction

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a fatal disease with a survival time of less than 5 years and prevalence of 3–4 per 100,000 persons in the United States^1,2. The neurodegenerative disorder was first described in the late 19th century and is characterized by the death of motor neurons in the brain, brainstem, and spinal cord, leading to paralysis^3,4. Although ALS has been studied for many decades, scientific and clinical results have only partially revealed that genetic mutation may play a role in the onset of disease^{5

–15}. In addition to hereditary factors, an unregulated neural transmitter system and environmental factors are the major factors influencing the progression of ALS¹⁶. These broad and general causes have confounded the investigation of therapies.

Although most cases of ALS are the sporadic form (sALS) of unknown etiology, ∼25% of ALS cases are the familial form (fALS), which is clinically and pathologically indistinguishable from sALS¹⁷. More detailed studies have been conducted on fALS than on sALS. Dominantly inherited gene mutations associated with fALS such as cytosolic copper-zinc superoxide dismutase 1 (SOD1), hexanucleotide repeat (chromosome 9 open reading frame 72, C9ORF72), tar DNA-binding protein 43 (TDP-43), fused in sarcoma (FUS), and other less frequent genes contribute to considerable genetic heterogeneity^{6,17

–23}. Among the ALS-related gene mutations, SOD1 mutants are responsible for 20% of fALS²⁴ and the synergistic effect of the mutant Alsin (also known as ALS2) and SOD1 are linked to the early onset of ALS^7,25. Genetically engineered cell lines or animal models for these genetic mutations are used to investigate the development of new drugs and to verify drug efficacy.

ALS modeling rodents or embryonic stem cells (ESCs) expressing ALS-causing genes have been generated to represent a specific subset of the syndrome in an effort to understand the onset and progression of ALS disease^{22,26

–32}. However, the transgene method alone cannot be used for mimicking the real physiology of motor neurons in sALS patients because it cannot completely correlate the genotype with the neuronal phenotype^26,33. Because animal and stem cell models for elucidating ALS pathogenesis have demonstrated shortcomings in recapitulating sALS patients, their capacity and application for the evaluation of therapeutic efficacy remain unmet needs. As an alternative, researchers have obtained induced pluripotent stem cells (iPSCs) from patients with neurodegenerative diseases, which have allowed the study of these cells with specific cell differentiation^2,34
–36.

Human iPSCs can be produced by reprogramming the somatic cells for a state of embryonic-like stem cell via delivering the required transcription factors (Fig. 1A and B)^37
–39. Such iPSCs can be directed to generate different kinds of neural cell types. iPSCs obtained from patients with ALS symptoms can be investigated at the molecular level to probe the changes in degeneration/death of motor neurons that trigger destruction of the neuromuscular junction^40
–42. Therefore, differentiated cells from ALS patients, such as those of the motor neuron type, can be used to identify drug candidates for ALS treatment. The present review focuses on existing medication and medical needs of ALS patients, advantages of using patients’ iPSCs, scope for improvement in the approaches of motor neuron differentiation and functional assays, and strategies for the evaluation of drug efficacy in ALS disease.

Fig. 1.

Schematic illustration showing that iPSCs generated from ALS patients differentiate into motor neurons for functional and morphological analysis. (A) ALS patients’ somatic cells are collected with donors’ informed consent under institutional review board monitoring (A) and the cells can be reprogrammed to the induced pluripotent state (B). After motor neuron differentiation of ALS patient’s iPSCs (C), further studies of the disease can be performed to assess physiological properties (D), providing a link to the level of maturation. The examination of morphological changes such as neurite length (E) subcellular aggregate (F), and patient-specific samples can be used to characterize the pathogenesis of ALS in patient-derived iPSCs. Nu: nucleus.

Currently Available Treatments and Potential Small Molecules

Drugs Approved by the U.S. Food and Drug Administration for ALS Treatment

Riluzole is the first available compound known to attenuate the progression and partly relieve the symptoms of ALS via depressing N-methyl-D-aspartate (NMDA) receptor- and α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor-mediated signaling^43,44. Riluzole has several side effects and extends survival only by an average of 2–3 months, so more effective ALS therapy is urgently needed^45,46. The recently approved molecule edaravone is a small-radical scavenger that can inhibit oxidative stress. Edaravone was initially used to treat acute ischemic stroke⁴⁷. It quenches the hydroxyl radical functional group and downregulates both radical-dependent and radical-independent lipid peroxidation⁴⁸. Previous results showed that edaravone could delay the degeneration of motor neurons in a murine model with mutated SOD1 expression⁴⁹ and data from a phase 2 trial in ALS patients consistently reported the effect of the drug in reducing oxidative stress⁵⁰. Although evidence supported these positive outcomes in a phase 3 trial of edaravone, the inconvenience of intravenous administration and the extremely restricted population of ALS patients caused physicians not to prescribe the drug⁵¹. In addition to the inconvenience and high treatment cost, the long-term efficacy and toxicity profile of edaravone have not yet been established. Therefore, the clinical needs and challenges in clinical trials for ALS patients still exist and much more efficient protocols for drug screening are required.

Small-Molecule Development for Clinical Application Targeting ALS

Because of extensive studies investigating small molecules, exploring mechanisms, and synthesizing new compounds, the scope of drug discovery is changing and scientists can combine the power of synthetic chemistry with advanced screening technologies for small-molecule development. These small molecules can be covalent bonding inhibitors, protein–protein interaction modulators, protein conformational allosteric regulators, or epigenetic controllers and they sometimes have effects on multiple targets at one time^52
–54. For example, olaparib, an ADP-ribose polymerase inhibitor, and imatinib, a tyrosine kinase inhibitor, can significantly reduce ovarian cancer and chronic myeloid leukemia cells, respectively^55,56. Furthermore, small molecules can potentially penetrate the blood–brain barrier into the central nervous system to treat patients with brain tumors or neurological diseases⁵⁷. Creating small molecules that target mutant proteins associated with ALS may be promising candidates for the treatment of ALS.

Drug development based on neuroprotective properties such as reducing oxidative stress and excitotoxicity and eliminating toxic aggregates/fragments may benefit ALS patients. Recently, several groups have shown that autophagy plays an important role in ALS pathogenesis^58
–60. The autophagy–lysosome machinery is the major system for removing abnormal aggregates through cytoplasmic protein degradation⁶¹. One of these molecules that has been preferentially examined using in vitro and in vivo ALS models and shows promise is a purified compound from a plant used in traditional Chinese medicine (Angelica sinensis), n-butylidenephthalide (n-BP). Evidence has suggested that accumulated mutant SOD1 can initiate autophagy in an animal model⁵⁹ and n-BP can extend the lifespans of the SOD1 murine model through modulating cellular autophagy and apoptosis in the spinal cord⁶⁰. Furthermore, findings also indicated that n-BP could reduce the death of motor neurons, relieve muscular atrophy, suppress neuroinflammation, and recover gastrocnemius muscle⁵⁹. Although the functions of n-BP in anti-apoptosis, anti-inflammation, anti-oxidation, and autophagy modulation have been revealed, the data were collected from mutated SOD1 in in vitro and in vivo models. Investigations based on ALS patients’ iPSCs may provide further information for the development of this drug candidate.

iPSCs Differentiate into Functional Motor Neuron Units

Differentiation into Motor Neurons

iPSCs can generate different subtypes of neural cells, such as neurons, motor neurons, astrocytes, and other cell types^35,62
–64; therefore, the characterization of these in vitro cells recapitulating in vivo ALS progression can be achieved. Previous studies reported that human ESCs have been differentiated successfully into motor neurons by exogenously expressing the mutated genes of ALS. The approaches of motor neuron differentiation have also been applied to iPSCs. fALS/sALS-derived motor neurons can be harvested and investigated for the development of new drugs (Fig. 1C). Crucial secreted signaling factors, such as bone morphogenetic protein (BMP), fibroblast growth factor (FGF), retinoic acid (RA), Sonic hedgehog (Shh), and Wnts and transforming growth factor-beta (TGFβ) signaling, which are involved in the patterning neural axis during brain development, have been used to direct iPSCs toward motor neurons^65

–68.

Motor neurons are classified as corticospinal upper motor neurons and spinal cord lower motor neurons (LMNs). The degeneration and death of motor neurons lead to the onset of neurodegenerative diseases such as ALS^69
–71. According to results obtained in different species^67,72

–75, signaling in the development of neuroectoderm has been shown to specify LMN fate^66,68. The process of motor neuron differentiation is time consuming, expensive, and inefficient in the acquisition of cells. After making efforts to fine-tune the protocols, two small molecules, LDN193189 and SB431542, were found to accelerate the differentiation of motor neurons through the inhibition of both BMP and TGFβ signaling and blocking mesoderm and endoderm fates⁷⁶. Therefore, more abundant motor neurons can be obtained from iPSCs in a shorter time period.

Functional Assay and Morphological Marker for Motor Neurons

The most extensive functional examination of differentiated motor neurons is detection of the electrophysiological action potential for evaluating the maturation of motor neurons in vitro ⁷⁶ (Fig. 1D). During the early stages of neural differentiation, voltage-gated ion channels need to be induced to generate an action potential. In addition, spontaneous action potentials require time to develop after the maturation of motor neurons⁷⁷. To achieve a high level of mature motor neurons, the transition between induced and spontaneously occurred action potentials requires the involvement of various factors such as synapse formation^78,79. To determine the propagation of electrical signals, protocols to direct the differentiation of motor neurons from iPSCs with the capability of synapse formation is critical.

Because ALS pathogenesis presents heterogeneous causes accompanied by distinct mechanisms linked to the onset and progression of ALS, imaging-based approaches are required to determine cellular/molecular changes and drug effects on ALS disease⁸⁰. For evaluation, information on cellular morphology can be obtained by automated data acquisition, thereby lowering the cost of drug screening in terms of labor. Both the fragmentation of neurites with reduced length and morphological swelling, the so-called bead-like structure resulting from abnormal protein aggregation (Fig. 1E and F)^22,81
–83, can be analyzed under the microscope. Such findings suggest that specific antibodies can be also used to label mutants for understanding the disease progression of ALS⁸⁴. These protein aggregates are expressed in vivo in native form, so the antibodies may not be available to recognize targets correctly and represent the real distribution or localization.

Use of ALS Patient-Derived iPSCs for Drug Development

Drug-Screening Platform via iPSCs from ALS Patients

During the process of novel drug development, safety and efficacy testing are costly and time consuming. Many clinical trials of ALS have been withdrawn or failed due to unexpected toxicity or lack of efficacy⁸⁵. The potential toxicities challenging clinical translation of drug candidates suggest that in vitro and in vivo nonhuman models might not be sufficient. To select effective therapies for ALS patients and to improve the success rate of drug selection, iPSCs have been used as models in many outstanding studies (Fig. 2A and Table 1)^{2,23,34,35,52,58,83,86

–90}. Egawa et al. recently reported an iPSC drug-screening assay in which they used several compounds targeting the epigenetic/transcriptional level of iPSC-derived motor neurons from ALS patients with the TDP-43 mutation². One of the compounds, anacardic acid, was shown to reverse part of the ALS phenotype found in motor neurons. This work can be a stepping stone to toward using ALS-specific motor neurons to verify candidate drugs.

Fig. 2.

Combination of human iPSC approach, high-throughput drug screening, and biomarker application can potentiate clinical candidate selection. (A) iPSCs derived from patients with ALS can be used for high-content drug screening to identify pathways and targets of small molecules with therapeutic potential. After preclinical studies, these small molecules may enter clinical trials with suitable administration routes (B) and the use of biomarkers can be used to calculate and determine drug efficacy (C). P-NFH: phosphorylated heavy chain of NF.

Table 1.

ALS Cell Models from Disease-Derived iPSCs.

ALS patient (responsible gene)	Neural cell type (differentiation marker)	Functional assay	Potential candidate	Author and year [reference number]
TDP-43 (Q343R, M337V, G298S)	Motor neuron (Isl-1, HB9, SMI-32, CHAT)	Motor neuron markers similar to healthy Shorter neurite TDP-43 aggregation (WB and IF)	Trichostatin A Spliceostatin A Anacardic acid Garcinol	Egawa et al., 2012²
SOD1 (L144F) TDP-43 (M337V)	Motor neuron (Isl-1, TuJ-1)	Action potential SOD1 aggregation (WB and IF) Synapse and motor neuron number	Kenpaullone	Yang et al., 2013⁵²
C9ORF72	Motor neuron (TuJ-1, SMI-32, CHAT)	Action potential C9ORF72 aggregation (WB) C9ORF72 RNA foci (FISH)	Small RNA molecule: C9ORF72 ASO	Sareen et al., 2013³⁵
TDP-43	Motor neuron (Isl-1, HB9, SMI-31)	Action potential TDP-43 aggregation (IF)	CDK inhibitor JNK inhibitor Triptolide FDA-approved cardiac glycosides Digoxin Lanatoside C Proscillaridin A	Burkhardt et al., 2013³⁴
C9ORF72	Motor neuron (TuJ-1)	Glutamate insult C9ORF72 aggregation (WB and Q-PCR) C9ORF72 RNA foci (FISH)	Small RNA molecules: ADARB2 siRNA Small RNA molecules: C9ORF72 ASO	Donnelly et al., 2013⁸⁸
SOD1 (A4V, D90A, G85S) C9ORF72 FUS (M511FS, H517Q)	Motor neuron (Isl-1, HB9)	Action potential Hyper-excitability Motor neuron number	Retigabine	Wainger et al., 2014⁸⁹
C9ORF72	Motor neuron (Isl-1, HB9, Tuj1, SMI32, CHAT, VGLUT1, NMDAR1, SYT1, SYP) Astrocyte (ALDH1, GFAP)	Action potential C9ORF72 RNA foci (FISH) Intracellular protein transport (FRAP) RanGAP1 aggregation (IHC)	Small RNA molecule: C9ORF72 ASO Porphyrin (TMPyP4 and KPT-276)	Zhang et al., 2015⁹⁰
SOD1 (D90A, A4V)	Motor neuron (Isl-1, Tuj1, CHAT) Astrocyte	Action potential NF aggregation (Q-PCR) Shorter neurite Luciferase activity	Riluzole Kenpaullone EphA inhibitor	Du et al., 2015⁸³
SOD1 (L144FVX, G93S) TDP-43 (M337V, Q343R, G298S) C9ORF72 sALS sALS	Motor neuron (HB9, SMI-32, CHAT)	Action potential SOD1 aggregation (WB) Autophagy Motor neuron number	Bosutinib Desatinib	Imamura et al., 2017⁵⁸
FUS (R521H, P525L)	Motor neuron (HB9, Isl-1, CHAT, SMI-32, Synapsin1, Tuj1)	Action potential Hypo-excitability FUS localization (IF) Axonal transport	Small RNA molecule: HDAC6 ASO ACY-738 and Tubastatin A	Guo et al., 2017²³

WB: Western blotting analysis; IF: immunofluorescence assay; FISH: fluorescence in situ hybridization; IHC: immunohistochemistry; FRAP: fluorescence recovery after photobleaching; Isl-1: Islet-1; HB9: Homeobox 9; Tuj1: beta III tubulin; SMI32: neurofilament H non-phosphorylated; CHAT: choline acetyltransferase; VGLUT1: vesicular glutamate transporter 1; NMDAR1: NMDA receptor 1; SYT1: synaptotagmin 1, SYP: synaptophysin; ALDH1: aldehyde dehydrogenase 1; GFAP: glial fibrillary acidic protein; ASO: anti-sense oligo-nucleotide; CDK: cyclin-dependent kinase; JNK: c-Jun N-terminal kinase

Motor neurons derived from patients with fALS or sALS were used to screen various kinase inhibitors, epigenetic modulators, anti-sense oligo-nucleotides (ASOs), or approved molecules for any other indication (Table 1). Furthermore, Wainger et al. used a high-throughput electrode array to detect the action potentials of variant ALS patients’ motor neurons (SOD1, C9ORF72, and FUS mutation) and revealed that retigabine could reduce the death of motor neurons by blocking hyperexcitability⁸⁹. The drug candidates identified by such methods can confirm the toxicity and efficacy of drugs in humans and retigabine has entered a phase 2 trial for efficacy evaluation (NCT02450552; estimated completion date: February 2018). Importantly, ALS-patient-specific iPSCs present many benefits, including the correct genetic background and pluripotency. The results from the above-mentioned drug-screening studies have shown that high-throughput approaches can produce abundant and useful information that can expedite and increase the probability of success for drug candidates entering clinical trials⁹¹ (Fig. 2B).

Although iPSCs are mainly generated from skin fibroblasts or peripheral blood from ALS patients, the pathogenic phenotypes may disappear. These iPSCs may be reverted to the early stage pluripotent cells. Thus, the recapitulation of a late onset of neurodegenerative disease cannot be fully achieved⁹². To generate iPSCs associated with the characterization of aging, oxidative stress, DNA-damaging and proteasome modulator agents are being tested to produce high-level maturation of patient-specific iPSC derivatives^93
–95. Previous reports indicated that AMPA receptor, a glutamate receptor, could mediate excitatory transmission in the brain; therefore, glutamate insult accelerates the aging process by allowing high level of calcium ions to enter the neurons^15,96. Such induction can be used to change the phenotypes of patient-derived iPSCs to mimic neurodegeneration. In addition, downregulation of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) can attenuate neuron death by manipulating the trafficking of the GluR2 subunit of the AMPA receptor within the cell membrane⁹⁷. Many small molecules modulating PTEN have been synthesized, so it may be a potential therapeutic strategy for medical intervention in ALS patients.

To verify the use of screening approaches and to develop reliable platforms for exploring the molecular underpinnings of ALS, multiple iPSC clones from different ALS patients and several markers are urgently required. Using at least two iPSC lines from patients with ALS in combination with automated and imaging-based techniques would acquire considerable information on cell morphology, formation of protein aggregates, and distribution/patterns of specific molecules by immunocytochemistry/immunocytochemistry or immunofluorescence staining. Moreover, high-throughput equipment has been used for examining small-molecule compounds in several studies. Nevertheless, there is no clear mechanism of neuron death that can clearly distinguish sALS from fALS. Large sample sizes are necessary to reveal the detailed and unique ALS pathogenesis, but the cost of reprogramming ALS patients’ fibroblasts for iPSCs remains high.

Biomarkers of Motor Neurons

Throughout the drug development process, biologically validated biomarkers are used to assess the subject’s response to a specific treatment. Biomarker analysis demonstrating the effect of the drug candidates on ALS targets is also important (Fig. 2C). Previous studies showed that CD40L, which is expressed by activated T cells and required for induced immune response, could be a treatment target for ALS patients. Moreover, inhibiting CD40L-mediated inflammatory responses can improve survival in animal studies^98,99. In addition to altered inflammatory gene expression, monocyte-expressed, ALS-specific, inflammation-related microRNA or the unregulated complement system can be treated with specific antibodies or inhibitors to delay ALS progression, extend survival, and improve motor function in animal models^100,101.

Abundant neurofilament (NF) proteins have been detected in the cerebral spinal fluid (CSF) or blood from SOD1 ^G93A mice^102
–104 (Fig. 2C). Among them, plasma containing the phosphorylated heavy chain of NF was thought to be associated with motor neuron death^105,106 (Fig. 2C). Moreover, NF aggregates (bead-like structure) can also be observed in ALS-patient-specific iPSCs with mutation of SOD1 ^A4V or SOD1 ^{D90A 81} (Fig. 1F).

Several studies have revealed that translational products of C9ORF72 repeats resulted in aggregation and were localized in the neurons of the central nervous system. This phenotype was seen in iPSC models^107,108. When small molecules bind to the GGGGCC repeat sequence, they can inhibit the formation of translational aggregates in the differentiated motor neurons derived from iPSCs (Table 1). In addition, peptide aggregation has been found in CSF from ALS patients with the C9ORF72 mutation¹⁰⁸ (Fig. 2C); therefore, this measurement is available for evaluating therapeutic efficacy.

Other reports about genetic mutations also found the formation of TDP-43 inclusion bodies, which was used as one of the biomarkers^2,34,109. Using enzyme-linked immunosorbent assay-based approaches, the TDP-43 level was found to be increased significantly in plasma and CSF from patients with ALS compared with healthy individuals. Although the discovery of biomarkers to distinguish ALS patients and healthy people are highly challenging, much more effective therapies may be investigated and developed with more biomarkers

Conclusion

Neurodegenerative diseases have a potentially disastrous impact on quality of life, so ongoing efforts to develop novel therapeutic drug candidates are of utmost importance^{99,110

–113}. The use of genetic manipulation in cell systems and nonhuman animal models may not predict the potential toxicity and lack of efficacy accurately in humans⁸⁵. Recent achievements in differentiation of patient-specific iPSCs into motor neurons have provided the basis to establish a platform to screen drug candidates, test toxicity, and confirm the efficacy of drugs in complicated fALS/sALS populations (Table 1). Although some constraints, such as the labor-intensive and high-cost procedure, protocols for generating fully mature motor neurons, detection methods of protein aggregates, applicable biomarkers, and basic mechanism of motor neuron death in sALS, need to be improved, the use of iPSC-dependent screening may accelerate the process of drug development. Following a systemic assessment (Fig. 2), studies of ALS may shed light on causes of disease and help to improve drug development in the future.

Footnotes

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by Everfront Biotech Inc.

References

Rothstein

. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol. 2009;65(suppl 1):S3–S9.

Egawa

Kitaoka

Tsukita

Naitoh

Takahashi

Yamamoto

Adachi

Kondo

Okita

Asaka

Aoi

Watanabe

Yamada

Morizane

Takahashi

Ayaki

Ito

Yoshikawa

Yamawaki

Suzuki

Watanabe

Hioki

et al. Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci Transl Med. 2012;4(145):145ra104.

Charcot

. Deux cas d’atrophie musculaire progressive avec lesions de la substance grise et des faisceaux anterolaterax de la moelle epiniere. Pathol. 1869;2:354–367.

Dimos

Rodolfa

Niakan

Weisenthal

Mitsumoto

Chung

Croft

Saphier

Leibel

Goland

Wichterle

Henderson

Eggan

. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science. 2008;321(5893):1218–1221.

Maruyama

Morino

Ito

Izumi

Kato

Watanabe

Kinoshita

Kamada

Nodera

Suzuki

Komure

Matsuura

Kobatake

Morimoto

Abe

Suzuki

Aoki

Kawata

Hirai

Kato

Ogasawara

Hirano

et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature. 2010;465(7295):223–226.

Rosen

Siddique

Patterson

Figlewicz

Sapp

Hentati

Donaldson

Goto

O’Regan

Deng

Rahmani

Krizus

McKenna-Yasek

Cayabyab

Gaston

Berger

Tanzi

Halperin

Herzfeldt

Van den Bergh

Hung

Bird

et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362(6415):59–62.

Yang

Hentati

Deng

Dabbagh

Sasaki

Hirano

Hung

Ouahchi

Yan

Azim

Cole

Gascon

Yagmour

Ben-Hamida

Pericak-Vance

Hentati

Siddique

. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat Genet. 2001;29(2):160–165.

Chen

Bennett

Huynh

Blair

Puls

Irobi

Dierick

Abel

Kennerson

Rabin

Nicholson

Auer-Grumbach

Wagner

De Jonghe

Griffin

Fischbeck

Timmerman

Cornblath

Chance

. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am J Hum Genet. 2004;74(6):1128–1135.

Nishimura

Mitne-Neto

Silva

Richieri-Costa

Middleton

Cascio

Kok

Oliveira

Gillingwater

Webb

Skehel

Zatz

. A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am J Hum Genet. 2004;75(5):822–831.

10.

Coyle

Puttfarcken

. Oxidative stress, glutamate, and neurodegenerative disorders. Science. 1993;262(5134):689–695.

11.

Lipton

Rosenberg

. Excitatory amino acids as a final common pathway for neurologic disorders. New Engl J Med. 1994;330(9):613–622.

12.

Benveniste

Drejer

Schousboe

Diemer

. Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J Neurochem. 1984;43(5):1369–1374.

13.

Rosenberg

Amin

Leitner

. Glutamate uptake disguises neurotoxic potency of glutamate agonists in cerebral cortex in dissociated cell culture. J Neurosci. 1992;12(1):56–61.

14.

Hollmann

O’Shea-Greenfield

Rogers

Heinemann

. Cloning by functional expression of a member of the glutamate receptor family. Nature. 1989;342(6250):643–648.

15.

Keinanen

Wisden

Sommer

Werner

Herb

Verdoorn

Sakmann

Seeburg

. A family of AMPA-selective glutamate receptors. Science. 1990;249(4968):556–560.

16.

Sutedja

Veldink

Fischer

Kromhout

Heederik

Huisman

Wokke

van den Berg

. Exposure to chemicals and metals and risk of amyotrophic lateral sclerosis: a systematic review. Amyotroph Lateral Scler. 2009;10(5–6):302–309.

17.

Wiedau-Pazos

Goto

Rabizadeh

Gralla

Roe

Lee

Valentine

Bredesen

. Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis. Science. 1996;271(5248):515–518.

18.

Majounie

Renton

Mok

Dopper

Waite

Rollinson

Chiò

Restagno

Nicolaou

Simon-Sanchez

van Swieten

Abramzon

Johnson

Sendtner

Pamphlett

Orrell

Mead

Sidle

Houlden

Rohrer

Morrison

Pall

et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012;11(4):323–330.

19.

Barmada

Skibinski

Korb

Rao

Finkbeiner

. Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. J Neurosci. 2010;30(2):639–649.

20.

Corrado

Del Bo

Castellotti

Ratti

Cereda

Penco

Sorarù

Carlomagno

Ghezzi

Pensato

Colombrita

Gagliardi

Cozzi

Orsetti

Mancuso

Siciliano

Mazzini

Comi

Gellera

Ceroni

D’Alfonso

Silani

. Mutations of FUS gene in sporadic amyotrophic lateral sclerosis. J Med Genet. 2010;47(3):190–194.

21.

Millecamps

Salachas

Cazeneuve

Gordon

Bricka

Camuzat

Guillot-Noël

Russaouen

Bruneteau

Pradat

Le Forestier

Vandenberghe

Danel-Brunaud

Guy

Thauvin-Robinet

Lacomblez

Couratier

Hannequin

Seilhean

Le Ber

Corcia

Camu

et al. SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis: genotype–phenotype correlations. J Med Genet. 2010;47(8):554–560.

22.

Wegorzewska

Bell

Cairns

Miller

Baloh

. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci USA. 2009;106(44):18809–18814.

23.

Guo

Naujock

Fumagalli

Vandoorne

Baatsen

Boon

Ordovás

Patel

Welters

Vanwelden

Geens

Tricot

Benoy

Steyaert

Lefebvre-Omar

Boesmans

Jarpe

Sterneckert

Wegner

Petri

Bohl

Vanden Berghe

et al. HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients. Nat Commun. 2017;8(1):861–875.

24.

Hart

. Pathogenic superoxide dismutase structure, folding, aggregation and turnover. Curr Opin Chem Biol. 2006;10(2):131–138.

25.

Kanekura

Hashimoto

Niikura

Aiso

Matsuoka

Nishimoto

. Alsin, the product of ALS2 gene, suppresses SOD1 mutant neurotoxicity through RhoGEF domain by interacting with SOD1 mutants. J Biol Chem. 2004;279(18):19247–19256.

26.

Gurney

. The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies. J Neurol Sci. 1997;152(suppl 1):S67–S73.

27.

Azzouz

Leclerc

Gurney

Warter

J-M

Poindron

Borg

. Progressive motor neuron impairment in an animal model of familial amyotrophic lateral sclerosis. Muscle Nerve. 1997;20(1):45–51.

28.

Dal Canto

Gurney

. Development of central nervous system pathology in a murine transgenic model of human amyotrophic lateral sclerosis. Am J Pathol. 1994;145(6):1271–1279.

29.

Collard

J-F

Côté

Julien

J-P

. Defective axonal transport in a transgenic mouse model of amyotrophic lateral sclerosis. Nature. 1995;375(6526):61–64.

30.

Karumbayaram

Kelly

Paucar

Roe

Umbach

Charles

Goldman

Kornblum

Wiedau-Pazos

. Human embryonic stem cell-derived motor neurons expressing SOD1 mutants exhibit typical signs of motor neuron degeneration linked to ALS. Dis Model Mech. 2009;2(3–4):189–195.

31.

Di Giorgio

Carrasco

Siao

Maniatis

Eggan

. Non–cell autonomous effect of glia on motor neurons in an embryonic stem cell–based ALS model. Nat Neurosci. 2007;10(5):608–614.

32.

Di Giorgio

Boulting

Bobrowicz

Eggan

. Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation. Cell Stem Cell. 2008;3(6):637–648.

33.

Zwiegers

Lee

Shaw

. Reduction in hSOD1 copy number significantly impacts ALS phenotype presentation in G37 R (line 29) mice: implications for the assessment of putative therapeutic agents. J Negat Results Biomed. 2014;13(1):14–22.

34.

Burkhardt

Martinez

Wright

Ramos

Volfson

Mason

Garnes

Dang

Lievers

Shoukat-Mumtaz

Martinez

Gai

Blake

Vaisberg

Grskovic

Johnson

Irion

Bright

Cooper

Nguyen

Griswold-Prenner

Javaherian

. A cellular model for sporadic ALS using patient-derived induced pluripotent stem cells. Mol Cell Neurosci. 2013;56:355–364.

35.

Sareen

O’Rourke

Meera

Muhammad

Grant

Simpkinson

Bell

Carmona

Ornelas

Sahabian

Gendron

Petrucelli

Baughn

Ravits

Harms

Rigo

Bennett

Otis

Svendsen

Baloh

. Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci Transl Med. 2013;5(208):208ra149.

36.

Alves

Dariolli

Jorge

Monteiro

Maximino

Martins

Strauss

Krieger

Callegaro

Chadi

. Gene expression profiling for human iPS-derived motor neurons from sporadic ALS patients reveals a strong association between mitochondrial functions and neurodegeneration. Front Cell Neurosci. 2015;9:289–313.

37.

Takahashi

Yamanaka

. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663–676.

38.

Takahashi

Tanabe

Ohnuki

Narita

Ichisaka

Tomoda

Yamanaka

. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861–872.

39.

Kwon

Kim

J-S

Cha

B-H

Park

K-S

Han

Park

K-S

Bae

Han

M-K

Kim

K-S

Lee

S-H

. The effect of fetal bovine serum (FBS) on efficacy of cellular reprogramming for induced pluripotent stem cell (iPSC) generation. Cell Transplant. 2016;25(6):1025–1042.

40.

Ona

Guégan

Chen

Jackson-Lewis

Andrews

Olszewski

Stieg

Lee

J-P

Przedborski

Friedlander

. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science. 2000;288(5464):335–339.

41.

Pasinelli

Houseweart

Brown

Cleveland

. Caspase-1 and-3 are sequentially activated in motor neuron death in Cu, Zn superoxide dismutase-mediated familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA. 2000;97(25):13901–13906.

42.

Nagai

Nagata

Chalazonitis

Jessell

Wichterle

Przedborski

. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci. 2007;10(5):615–622.

43.

De Sarro

Siniscalchi

Ferreri

Gallelli

De Sarro

. NMDA and AMPA/kainate receptors are involved in the anticonvulsant activity of riluzole in DBA/2 mice. Eur J Pharmacol. 2000;408(1):25–34.

44.

Lamanauskas

Nistri

. Riluzole blocks persistent Na+ and Ca2+ currents and modulates release of glutamate via presynaptic NMDA receptors on neonatal rat hypoglossal motoneurons in vitro. Eur J Neurosci. 2008;27(10):2501–2514.

45.

Groeneveld

Van Kan

Kalmijn

Veldink

Guchelaar

H-J

Wokke

Van den Berg

. Riluzole serum concentrations in patients with ALS Associations with side effects and symptoms. Neurology. 2003;61(8):1141–1143.

46.

Bensimon

Lacomblez

Meininger

; ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med. 1994;330(9):585–591.

47.

Edaravone Acute Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis. 2003;15(3):222–229.

48.

Watanabe

Tahara

Todo

. The novel antioxidant edaravone: from bench to bedside. Cardiovasc Ther. 2008;26(2):101–114.

49.

Ito

Wate

Zhang

Ohnishi

Kaneko

Ito

Nakano

Kusaka

. Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Exp Neurol. 2008;213(2):448–455.

50.

Yoshino

Kimura

. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study). Amyotroph Lateral Sc. 2006;7(4):247–251.

51.

Tanaka

Sakata

Palumbo

Akimoto

. A 24-week, phase III, double-blind, parallel-group study of edaravone (MCI-186) for treatment of amyotrophic lateral sclerosis (ALS). Neurology. 2016;86(suppl 16):P3.189.

52.

Yang

Gupta

Kim

Powers

Cerqueira

Wainger

Ngo

Rosowski

Schein

Ackeifi

Arvanites

Davidow

Woolf

Rubin

. A small molecule screen in stem-cell-derived motor neurons identifies a kinase inhibitor as a candidate therapeutic for ALS. Cell Stem Cell. 2013;12(6):713–726.

53.

Ray

Nowak

Brown

Lansbury

. Small-molecule-mediated stabilization of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants against unfolding and aggregation. Proc Natl Acad Sci USA. 2005;102(10):3639–3644.

54.

Belzil

Bauer

Prudencio

Gendron

Stetler

Yan

Pregent

Daughrity

Baker

Rademakers

Boylan

Patel

Dickson

Petrucelli

. Reduced C9orf72 gene expression in c9FTD/ALS is caused by histone trimethylation, an epigenetic event detectable in blood. Acta Neuropathol. 2013;126(6):895–905.

55.

Kim

Ison

McKee

Zhang

Tang

Gwise

Sridhara

Lee

Tzou

Philip

Chiu

Ricks

Palmby

Russell

Ladouceur

Pfuma

Zhao

Liu

Venugopal

Ibrahim

Pazdur

. FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy. Clin Cancer Res. 2015;21(19):4257–4261.

56.

Druker

Guilhot

O’Brien

Gathmann

Kantarjian

Gattermann

Deininger

Silver

Goldman

Stone

Cervantes

Hochhaus

Powell

Gabrilove

Rousselot

Reiffers

Cornelissen

Hughes

Agis

Fischer

Verhoef

et al; IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408–2417.

57.

Pardridge

. Blood–brain barrier delivery. Drug Discov Today. 2007;12(1):54–61.

58.

Imamura

Izumi

Watanabe

Tsukita

Woltjen

Yamamoto

Hotta

Kondo

Kitaoka

Ohta

Tanaka

Watanabe

Morita

Takuma

Tamaoka

Kunath

Wray

Furuya

Era

Makioka

Okamoto

Fujisawa

et al. The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Sci Transl Med. 2017;9(391):eaaf3962.

59.

Zhou

Zhang

Chen

. n-butylidenephthalide treatment prolongs life span and attenuates motor neuron loss in SOD1G93A mouse model of amyotrophic lateral sclerosis. CNS Neurosci Ther. 2017;23(5):375–385.

60.

Hsueh

K-W

Chiou

T-W

Chiang

S-F

Yamashita

Abe

Borlongan

Sanberg

Lin

S-Z

Harn

H-J

. Autophagic down-regulation in motor neurons remarkably prolongs the survival of ALS mice. Neuropharmacology. 2016;108:152–160.

61.

Kabeya

Mizushima

Ueno

Yamamoto

Kirisako

Noda

Kominami

Ohsumi

Yoshimori

. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 2000;19(21):5720–5728.

62.

Serio

Bilican

Barmada

Ando

Zhao

Siller

Burr

Haghi

Story

Nishimura

Carrasco

Phatnani

Shum

Wilmut

Maniatis

Shaw

Finkbeiner

Chandran

. Astrocyte pathology and the absence of non-cell autonomy in an induced pluripotent stem cell model of TDP-43 proteinopathy. Proc Natl Acad Sci USA. 2013;110(12):4697–4702.

63.

Ogawa

S-i

Tokumoto

Miyake

Nagamune

. Induction of oligodendrocyte differentiation from adult human fibroblast-derived induced pluripotent stem cells. In Vitro Cell Dev-An. 2011;47(7):464–469.

64.

Liu

Spusta

Lassiter

Stark

Höke

Rao

Zeng

. Human neural crest stem cells derived from human ESCs and induced pluripotent stem cells: induction, maintenance, and differentiation into functional schwann cells. Stem Cell Transl Med. 2012;1(4):266–278.

65.

B-Y

Weick

L-X

Zhang

X-Q

Thomson

Zhang

S-C

. Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. Proc Natl Acad Sci USA. 2010;107(9):4335–4340.

66.

LaVaute

Yoo

Pankratz

Weick

Gerstner

Zhang

. Regulation of neural specification from human embryonic stem cells by BMP and FGF. Stem Cells. 2009;27(8):1741–1749.

67.

Jones

Zhang

LaVaute

Zhang

. Directed differentiation of ventral spinal progenitors and motor neurons from human embryonic stem cells by small molecules. Stem Cells. 2008;26(4):886–893.

68.

Nordström

Jessell

Edlund

. Progressive induction of caudal neural character by graded Wnt signaling. Nat Neurosci. 2002;5(6):525–532.

69.

Gurney

Chiu

Dal Canto

Polchow

Alexander

Caliendo

Hentati

Kwon

Deng

. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science. 1994;264(5166):1772–1775.

70.

Ravits

Paul

Jorg

. Focality of upper and lower motor neuron degeneration at the clinical onset of ALS. Neurology. 2007;68(19):1571–1575.

71.

Mitsumoto

Ulug

Pullman

Gooch

Chan

Tang

Mao

Hays

Floyd

Battista

Montes

Hayes

Dashnaw

Kaufmann

Gordon

Hirsch

Levin

Rowland

Shungu

. Quantitative objective markers for upper and lower motor neuron dysfunction in ALS. Neurology. 2007;68(17):1402–1410.

72.

Wichterle

Lieberam

Porter

Jessell

. Directed differentiation of embryonic stem cells into motor neurons. Cell. 2002;110(3):385–397.

73.

Lindvall

Kokaia

Martinez-Serrano

. Stem cell therapy for human neurodegenerative disorders–how to make it work. Nat Med. 2004;10(suppl):S42–S50.

74.

Harper

Krishnan

Darman

Deshpande

Peck

Shats

Backovic

Rothstein

Kerr

. Axonal growth of embryonic stem cell-derived motoneurons in vitro and in motoneuron-injured adult rats. Proc Natl Acad Sci USA. 2004;101(18):7123–7128.

75.

Karumbayaram

Novitch

Patterson

Umbach

Richter

Lindgren

Conway

Clark

Goldman

Plath

Wiedau-Pazos

Kornblum

Lowry

. Directed differentiation of human-induced pluripotent stem cells generates active motor neurons. Stem Cells. 2009;27(4):806–811.

76.

Maury

Côme

Piskorowski

Salah-Mohellibi

Chevaleyre

Peschanski

Martinat

Nedelec

. Combinatorial analysis of developmental cues efficiently converts human pluripotent stem cells into multiple neuronal subtypes. Nat Biotechnol. 2015;33(1):89–96.

77.

Johnson

Weick

Pearce

Zhang

S-C

. Functional neural development from human embryonic stem cells: accelerated synaptic activity via astrocyte coculture. J Neurosci. 2007;27(12):3069–3077.

78.

Suzuki

McHugh

Tork

Shelley

Klein

Aebischer

Svendsen

. GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS. PLoS One. 2007;2(8):e689.

79.

Krakora

Mulcrone

Meyer

Lewis

Bernau

Gowing

Zimprich

Aebischer

Svendsen

Suzuki

. Synergistic effects of GDNF and VEGF on lifespan and disease progression in a familial ALS rat model. Mol Ther. 2013;21(8):1602–1610.

80.

Wang

Farr

Zeiss

Rodriguez-Gil

Wilson

Furtak

Rutkowski

Kaufman

Ruse

Yates

Perrin

Feany

Horwich

. Progressive aggregation despite chaperone associations of a mutant SOD1-YFP in transgenic mice that develop ALS. Proc Natl Acad Sci USA. 2009;106(5):1392–1397.

81.

Chen

Qian

Cao

Petersen

Liu

Blackbourn

Huang

Errigo

Yin

Ayala

Zhang

. Modeling ALS with iPSCs reveals that mutant SOD1 misregulates neurofilament balance in motor neurons. Cell Stem Cell. 2014;14(6):796–809.

82.

Mori

Weng

Arzberger

May

Rentzsch

Kremmer

Schmid

Kretzschmar

Cruts

Van Broeckhoven

Haass

Edbauer

. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science. 2013;339(6125):1335–1338.

83.

Z-W

Chen

Liu

Qian

Huang

CT-L

Zhong

Fan

Zhang

S-C

. Generation and expansion of highly-pure motor neuron progenitors from human pluripotent stem cells. Nat Commun. 2015;6:6626–6634.

84.

Chou

Wang

Taniguchi

. Role of SOD-1 and nitric oxide/cyclic GMP cascade on neurofilament aggregation in ALS/MND. J Neurol Sci. 1996;139(suppl):16–26.

85.

Mitsumoto

Brooks

Silani

. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol. 2014;13(11):1127–1138.

86.

Heemskerk

. High throughput drug screening. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5(suppl 1):19–21.

87.

Aiken

Tobin

Schweitzer

. A cell-based screen for drugs to treat Huntington’s disease. Neurobiol Dis. 2004;16(3):546–555.

88.

Donnelly

Zhang

Pham

Haeusler

Mistry

Vidensky

Daley

Poth

Hoover

Fines

Maragakis

Tienari

Petrucelli

Traynor

Wang

Rigo

Bennett

Blackshaw

Sattler

Rothstein

. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. 2013;80(2):415–428.

89.

Wainger

Kiskinis

Mellin

Wiskow

Han

Sandoe

Perez

Williams

Lee

Boulting

Berry

Brown

Cudkowicz

Bean

Eggan

Woolf

. Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. Cell Rep. 2014;7(1):1–11.

90.

Zhang

Donnelly

Haeusler

Grima

Machamer

Steinwald

Daley

Miller

Cunningham

Vidensky

Gupta

Thomas

Hong

Chiu

Huganir

Ostrow

Matunis

Wang

Sattler

Lloyd

Rothstein

. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature. 2015;525(7567):56–61.

91.

Madill

McDonagh

Vajda

McLoughlin

O’Brien

Hardiman

Shen

. Amyotrophic lateral sclerosis patient iPSC-derived astrocytes impair autophagy via non-cell autonomous mechanisms. Mol Brain. 2017;10(1):22–33.

92.

Liu

G-H

Ding

Belmonte

JCI

. iPSC technology to study human aging and aging-related disorders. Curr Opin Cell Biol. 2012;24(6):765–774.

93.

Lopez-Gonzalez

Gendron

Karydas

Tran

Yang

Petrucelli

Miller

Almeida

Gao

F-B

. Poly (GR) in C9ORF72-related ALS/FTD compromises mitochondrial function and increases oxidative stress and DNA damage in iPSC-derived motor neurons. Neuron. 2016;92(2):383–391.

94.

Hyun

Lee

Halliwell

Jenner

. Proteasomal inhibition causes the formation of protein aggregates containing a wide range of proteins, including nitrated proteins. J Neurochem. 2003;86(2):363–373.

95.

Zhang

Jansen-West

Gendron

Bieniek

Lin

Sasaguri

Caulfield

Hubbard

Daughrity

Chew

Belzil

Prudencio

Stankowski

Castanedes-Casey

Whitelaw

Ash

DeTure

Rademakers

Boylan

Dickson

Petrucelli

. Aggregation-prone c9FTD/ALS poly (GA) RAN-translated proteins cause neurotoxicity by inducing ER stress. Acta Neuropathol. 2014;128(4):505–524.

96.

Yang

Wang

Ismail

Ashman

Valori

Wang

Gao

Higginbottom

Ince

Azzouz

Shaw

Ning

. PTEN regulates AMPA receptor-mediated cell viability in iPS-derived motor neurons. Cell Death Dis. 2014;5(2):e1096.

97.

Liu

Wang

Long

Wan

Jiang

Wang

. Inhibiting PTEN protects hippocampal neurons against stretch injury by decreasing membrane translocation of AMPA receptor GluR2 subunit. PLoS One. 2013;8(6):e65431.

98.

Lincecum

Vieira

Wang

Thompson

De Zutter

Kidd

Moreno

Sanchez

Carrion

Levine

Al-Nakhala

Sullivan

Gill

Perrin

. From transcriptome analysis to therapeutic anti-CD40 L treatment in the SOD1 model of amyotrophic lateral sclerosis. Nat Genet. 2010;42(5):392–399.

99.

Moviglia

Moviglia-Brandolino

Varela

Albanese

Piccone

Echegaray

Martinez

Blasseti

Farias

Farina

Perusso

Gaeta

. Feasibility, safety, and preliminary proof of principles of autologous neural stem cell treatment combined with T-cell vaccination for ALS patients. Cell Transplant. 2012;21(suppl 1):S57–S63.

100.

Butovsky

Siddiqui

Gabriely

Lanser

Dake

Murugaiyan

Doykan

Gali

Iyer

Lawson

Berry

Krichevsky

Cudkowicz

Weiner

. Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J Clin Invest. 2012;122(9):3063–3087.

101.

El Idrissi

Bosch

Ramaglia

Aronica

Baas

Troost

. Complement activation at the motor end-plates in amyotrophic lateral sclerosis. J Neuroinflamm. 2016;13(1):72–83.

102.

Pasinetti

Ungar

Lange

Yemul

Deng

Yuan

Brown

Cudkowicz

Newhall

Peskind

Marcus

. Identification of potential CSF biomarkers in ALS. Neurology. 2006;66(8):1218–1222.

103.

Noto

Shibuya

Sato

Kanai

Misawa

Sawai

Mori

Uchiyama

Isose

Nasu

Sekiguchi

Fujimaki

Kasai

Tokuda

Nakagawa

Kuwabara

. Elevated CSF TDP-43 levels in amyotrophic lateral sclerosis: specificity, sensitivity, and a possible prognostic value. Amyotroph Lateral Scler. 2011;12(2):140–143.

104.

Verstraete

Kuiperij

van Blitterswijk

Veldink

Schelhaas

van den Berg

Verbeek

. TDP-43 plasma levels are higher in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2012;13(5):446–451.

105.

Lehnert

Costa

de Carvalho

Kirby

Kuzma-Kozakiewicz

Morelli

Robberecht

Shaw

Silani

Steinacker

Tumani

Van Damme

Ludolph

Otto

. Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(5–6):344–350.

106.

Boylan

Yang

Crook

Overstreet

Heckman

Wang

Borchelt

Shaw

. Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF-H) in blood of ALS model rodents and ALS patients: evaluation of blood pNF-H as a potential ALS biomarker. J Neurochem. 2009;111(5):1182–1191.

107.

Almeida

Gascon

Tran

Chou

Gendron

Degroot

Tapper

Sellier

Charlet-Berguerand

Karydas

Seeley

Boxer

Petrucelli

Miller

Gao

. Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC-derived human neurons. Acta Neuropathol. 2013;126(3):385–399.

108.

Zhang

Gendron

Bauer

Chew

Yang

Fostvedt

Jansen-West

Belzil

Desaro

Johnston

Overstreet

Todd

Berry

Cudkowicz

Boeve

Dickson

Floeter

Traynor

Morelli

Ratti

et al. Discovery of a biomarker and lead small molecules to target r (GGGGCC)-associated defects in c9FTD/ALS. Neuron. 2014;83(5):1043–1050.

109.

Junttila

Kuvaja

Hartikainen

Siloaho

Helisalmi

Moilanen

Kiviharju

Jansson

Tienari

Remes

Herukka

. Cerebrospinal fluid TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis patients with and without the C9ORF72 hexanucleotide expansion. Dement Geriatr Cogn Dis Extra. 2016;6(1):142–149.

110.

Silva

Sousa

Haddad

Azevedo

Soares

Peixoto

Soares

Issa

Felipe

Branco

Addad

Moreira

Tuche

Mesquita

Drumond

Junior

Rochitte

Luz

Rabischoffisky

Nogueira

Vieira

Junior

et al. Autologous bone-marrow mononuclear cell transplantation after acute myocardial infarction: comparison of two delivery techniques. Cell Transplant. 2009;18(3):343–352.

111.

Kim

Lee

Kim

Lim

Kim

. Transplantation of human adipose tissue-derived stem cells delays clinical onset and prolongs life span in ALS mouse model. Cell Transplant. 2014;23(12):1585–1597.

112.

Mejía-Toiber

Castillo

Giordano

. Strategies for the development of cell lines for ex vivo gene therapy in the central nervous system. Cell Transplant. 2011;20(7):983–1001.

113.

Lin

S-Z

. Translational cell therapies in regenerative medicine and cancers. Cell Transplant. 2016;25(5):781–782.